Pseudomonas infection in CF: AUTHOR'S REPLY

December 2000
Thorax;Dec2000, p1071
Academic Journal
No abstract available.


Related Articles

  • Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa. Pitt, T.L. // Thorax;Nov2002, Vol. 57 Issue 11, p921 

    Editorial. Focuses on cross infection of cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Mortality rate of CF patients; Choice of antimicrobial compounds; Drug resistance.

  • Effect of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. Worlitzch, Dieter; Tarran, Robert; Ulrich, Martina; Schwab, Ute; Cekici, Aynur; Meyer, Keith C.; Birrer, Peter; Bellon, Gabriel; Berger, Jurgen; Weiss, Tilo; Botzenhart, Konrad; Yankaskas, James R.; Randell, Scott; Boucher, Richard C.; Doring, Gerd // Journal of Clinical Investigation;2/1/2002, Vol. 109 Issue 3, p317 

    Presents a study which investigated whether airway mucus hypoxia was present in thickened cystic fibrosis (CF) mucus before infection in CF patients with the lung disease, Pseudomonas aeruginosa. Methods used; Evidence for growth of Pseudomonas aeruginosa; Depletion of oxygen within...

  • Cystic fibrosis basic science: what's new?  // Thorax;Dec2004 Supplement, Vol. 59, p24 

    The article presents some papers related to cystic fibrosis (CF). Much of the morbidity and mortality seen in CF is related to chronic infection of the respiratory tract with Pseudomonas aeruginosa (Pa). Adherence of Pa is increased to CF as compared with non-CF human nasal epithelium and is...

  • Cystic fibrosis, primary ciliary dyskinesia and non-cystic fibrosis bronchiectasis: update 2008e11. Flight, W. G.; Jones, A. M. // Thorax;Jul2012, Vol. 67 Issue 7, p645 

    A review is presented of key clinical papers published in Thorax and elsewhere between 2008 and April 2011 which have advanced our understanding of cystic fibrosis (CF), primary ciliary dyskinesia and non-CF bronchiectasis. Studies were identified through searches of the Thorax archive and the...

  • Priming of Blood Neutrophils in Children with Cystic Fibrosis: Correlation between Functional and... Witko-Sarsat, Veronique; Halbwachs-Mecarelli, Lise; Sermet-Gaudelus, Isabelle; Bessou, Gilles; Lenoir, Gerard; Allen, Robert C.; Descamps-Latscha, Beatrice // Journal of Infectious Diseases;1/1/99, Vol. 179 Issue 1, p151 

    Examines the functions of blood phagocyte opsonin receptor CR1 (CD35) and CR3 (CD11b) in cystic fibrosis (CF) patients with endobronchial Staphylococcus aureus or Pseudomonas aeruginosa chronic infection, CF patients without infection, heterozygous, non-CF patients with chronic pulmonary...

  • Patients with cystic fibrosis (CF) now have provincial formulary access to Novartis' TOBI PODHALER in Quebec.  // PharmacoEconomics & Outcomes News;10/15/2011, Issue 639, p9 

    The article reports that Novartis' PODHALER, a dry-powder formulation of tobramycin in the form of breath-activated inhaler, is available for patients with cystic fibrosis (CF) in Quebec for treatment of Pseudomonas aeruginosa (Pa) infections.

  • Corus Pharma: clearing the air.  // PharmaWatch: Monthly Review;Jun2005, Vol. 4 Issue 6, p29 

    The article announces the initiation of Phase III AIR-CF2 trials for the safety and effectiveness of aztreonam lysinate inhaler as treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients by Corus Pharma Inc.

  • Case Fourteen: Full of Slime. Muldoon, Jean F.; Mortensen, Joel E. // Journal of Continuing Education Topics & Issues;Jan2007, Vol. 9 Issue 1, p26 

    The article discusses a clinical microbiology case involving a 14-year-old female patient with cystic fibrosis (CF). The disease is characterized by chronic obstructive pulmonary disease, exocrine pancreatic insufficiency and abnormally high sweat electrolytes. Several infectious agents are...

  • Pseudomonas aeruginosa Eradication: How Do We Measure Success? Zemanick, Edith T.; Laguna, Theresa A. // Clinical Infectious Diseases;9/1/2015, Vol. 61 Issue 5, p716 

    The author reflects on a study by N. Mayer-Hamblett and colleagues to examine the clinical and microbiolgical impact of eradication of Pseudomonas aeruginosa (Pa) on outcome measures in children with cystic fibrosis (CF). He informs that early eradication approaches have been effective in...

  • Normal Range for Pulmonary Artery Systolic Pressure. Machado, Roberto F.; Hsue, Priscilla Y.; Barnett, Christopher F. // JAMA: Journal of the American Medical Association;5/7/2008, Vol. 299 Issue 17, p2022 

    The article presents a reply to a letter to the editor discussing the article "Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection," by CF Barnett, PY Hsue, RF Machado, et al published in a previous issue.


Read the Article


Sign out of this library

Other Topics